{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04055818",
            "orgStudyIdInfo": {
                "id": "2019-0631"
            },
            "secondaryIdInfos": [
                {
                    "id": "P01HL146372",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P01HL146372"
                },
                {
                    "id": "R44HL135896",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R44HL135896"
                }
            ],
            "organization": {
                "fullName": "EpiDestiny, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease",
            "officialTitle": "Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-nicotinamide-with-oral-tetrahydrouridine-and-decitabine-to-treat-high-risk-sickle-cell-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-04",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2020-01-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-03-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-04-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-08-12",
            "studyFirstSubmitQcDate": "2019-08-12",
            "studyFirstPostDateStruct": {
                "date": "2019-08-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-04-04",
            "lastUpdatePostDateStruct": {
                "date": "2023-04-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "EpiDestiny, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                },
                {
                    "name": "National Heart, Lung, and Blood Institute (NHLBI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).",
            "detailedDescription": "A randomized control trial comparing oral THU-decitabine to nicotinamide (1:1 randomization), and then comparing the effects of the combination of nicotinamide with THU-decitabine vs either treatment alone. Treatment with each agent alone is for 12 weeks followed by the combination for a further 12 weeks. Patients have the option to enter an extension phase of combination treatment for an additional 24 weeks (total of 48 weeks)"
        },
        "conditionsModule": {
            "conditions": [
                "Sickle Cell Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "1:1 Randomization",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Nicotinamide",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Nicotinamide 1000 mg twice daily",
                    "interventionNames": [
                        "Drug: Nicotinamide"
                    ]
                },
                {
                    "label": "THU Decitabine",
                    "type": "EXPERIMENTAL",
                    "description": "Oral 250 mg THU and 5 mg decitabine Once per week",
                    "interventionNames": [
                        "Drug: Nicotinamide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nicotinamide",
                    "description": "Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination",
                    "armGroupLabels": [
                        "Nicotinamide",
                        "THU Decitabine"
                    ],
                    "otherNames": [
                        "Decitabine",
                        "Tetrahydrouridine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Blood Hemoglobin",
                    "description": "Measure hemoglobin function",
                    "timeFrame": "12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 years or older.\n* Written informed consent provided by the subject before study entry.\n* Confirmed sickle cell disease (SCD) as determined by hemoglobin electrophoresis or liquid chromatography.\n* Subject is in his/her steady state and not having any acute complication due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome in the past 14 days).\n* Weight at least 40kg\n* Regular compliance with comprehensive care and previous therapy.\n* Symptomatic SCD is defined as having one of following, despite at least 6 months of hydroxyurea therapy, or refuse to take hydroxyurea for personal reasons: fetal hemoglobin \\<0.5 g/dL, or 3 or more pain episodes per year requiring parenteral narcotics, or 1 or more acute chest syndrome episodes, or Hemoglobin \\<9 g/dL and absolute reticulocyte count \\<250,000/mm3.\n\nExclusion Criteria:\n\n* Inability to give informed consent.\n* Experienced severe sepsis or septic shock within the previous 12 weeks.\n* Last HU dose was ingested within the previous 4 weeks.\n* Currently pregnant or breast-feeding.\n* Alanine Aminotransferase (ALT) \u2265 3 times the upper limit of normal or albumin \\<2.0 mg/dL or direct (conjugated) bilirubin \u2265 1.5 mg/dl.\n* Serum creatinine \\>2.9 mg/dL and calculated creatinine clearance \\<30 mL/min.\n* Platelet count \\>800 x 109/L.\n* Absolute neutrophil count \\<1.5 x 109/L.\n* Female of active childbearing potential who is unwilling to use at least one of the two following forms of birth control: (i) not having heterosexual sexual contact beginning at the screening visit and continuing until 4 weeks after the last dose of decitabine OR (ii) intrauterine device (IUD).\n* Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a female with child-bearing potential, beginning at the screening visit and continuing until 4 weeks after taking the last dose of THU and decitabine. This requirement applies also to males who have had a successful vasectomy.\n* Altered mental status or recurrent seizures requiring anti-seizure medications.\n* Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely.\n* Concurrent diagnosis of malignancy including known Myelodysplastic syndrome, leukemia, or an abnormal karyotype.\n* New York Heart Association (NYHA) class III/IV status.\n* Eastern Co-operative Oncology Group (ECOG) performance status \u22653.\n* Participant is on chronic transfusion therapy\n* Known history of illicit drug or alcohol abuse within the past 12 months.\n* Other experimental or investigational drug therapy in the past 28 days.\n* Taking l-glutamine within the last 28 days\n* Being positive for HIV infection",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lani Krauz",
                    "role": "CONTACT",
                    "phone": "312-413-0242",
                    "email": "LIgnacio@UIC.EDU"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Robert Molokie",
                    "affiliation": "University of Illinois at Chicago College of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Illinois at Chicago College of Medicine",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lani Krauz",
                            "role": "CONTACT",
                            "phone": "312-413-0242",
                            "email": "Llgnacio@UIC.EDU"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000755",
                    "term": "Anemia, Sickle Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009536",
                    "term": "Niacinamide"
                },
                {
                    "id": "D000077209",
                    "term": "Decitabine"
                },
                {
                    "id": "D000013767",
                    "term": "Tetrahydrouridine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000014803",
                    "term": "Vitamin B Complex"
                },
                {
                    "id": "D000014815",
                    "term": "Vitamins"
                },
                {
                    "id": "D000018977",
                    "term": "Micronutrients"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12476",
                    "name": "Niacinamide",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12465",
                    "name": "Niacin",
                    "relevance": "LOW"
                },
                {
                    "id": "M12479",
                    "name": "Nicotinic Acids",
                    "relevance": "LOW"
                },
                {
                    "id": "M17558",
                    "name": "Vitamins",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M1697",
                    "name": "Decitabine",
                    "asFound": "Derived",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16535",
                    "name": "Tetrahydrouridine",
                    "asFound": "Flagyl",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M21009",
                    "name": "Micronutrients",
                    "relevance": "LOW"
                },
                {
                    "id": "M16885",
                    "name": "Trace Elements",
                    "relevance": "LOW"
                },
                {
                    "id": "T455",
                    "name": "Nicotinamide",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T453",
                    "name": "Niacin",
                    "relevance": "LOW"
                },
                {
                    "id": "T454",
                    "name": "Niacinamide",
                    "relevance": "LOW"
                },
                {
                    "id": "T456",
                    "name": "Nicotinic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T471",
                    "name": "Vitamin B3",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}